Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2023 | CARTITUDE-1 final results: cilta-cel in heavily pretreated patients with R/R myeloma

Yi Lin • 4 Jun 2023
ASCO 2023
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1 CARTITUDE-4

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the final results of the CARTITUDE-1 trial (NCT03548207), which is evaluating ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory (R/R) multiple myeloma. Dr Lin summarizes the median progression-free survival (PFS) observed in patients, and further shares her excitement for the Phase III CARTITUDE-4 trial (NCT04181827). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yi Lin

Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5 1:41
Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5
Yi Lin • 4 Sep 2025
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma 2:02
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma
Yi Lin • 4 Sep 2025
Guidance for junior researchers entering the cellular therapy field 1:55
Guidance for junior researchers entering the cellular therapy field
Yi Lin • 4 Sep 2025
The transformative effect of immunotherapies on the treatment landscape of DLBCL 3:06
The transformative effect of immunotherapies on the treatment landscape of DLBCL
Yi Lin • 4 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals